Matteo Santoni
@MatteoSantoniMD
Followers
62
Following
85
Media
0
Statuses
58
Joined November 2024
Just out! Patients who permanently discontinue immunotherapy treatment, due to SirAE, after completing at least 3 months, have the same OS as patients who continue treatment continuously! This is the largest RWE study in this RCC setting! Congrats to ARON! https://t.co/qr89mvfH8H
onlinelibrary.wiley.com
New immunotherapy drugs have expanded treatment options for renal cell carcinoma (RCC). However, a significant proportion of patients ultimately discontinue immunotherapy, typically because of...
0
3
6
CheckMate-9ER: cosa emerge dall’osservazione real life di ARON-1 su nivolumab + cabozantinib nel carcinoma renale metastatico e come questi dati influenzano la selezione del trattamento di prima linea del mRCC? Lo abbiamo chiesto a Matteo Santoni a#ESMO25
https://t.co/g1g2u6EKQx
0
1
1
Carcinoma prostatico ormono-sensibile metastatico: quali conferme arrivano dalla real life sull’utilizzo di darolutamide + terapia di deprivazione androgenica (ADT) + docetaxel testato nel trial ARASENS? Lo abbiamo chiesto a Francesco Massari a #ESMO25
https://t.co/HlKqul1mK2
0
2
2
Quali sono le RWE da ARON-2EV su enfortumab vedotin e come confermano o modificano il posizionamento sequenziale di enfortumab vedotin dopo mantenimento con avelumab nel carcinoma uroteliale avanzato? Lo abbiamo chiesto a Daniele Santini a #ESMO25
https://t.co/bJcOXIJjYv
0
1
1
Quali RWE emergono da ARON-3 sul confronto tra Lu-177 PSMA e cabazitaxel, e cosa suggeriscono circa le strategie di trattamento del carcinoma prostatico resistente alla castrazione? Lo abbiamo chiesto a Matteo Santoni, che abbiamo incontrato a #ESMO25
https://t.co/YTM3Vvyfl5
0
1
3
Efficacy of EV After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma. Out now on @EurUrolOpen the RWE by @aron_project
0
11
24
Sarcomatoid Differentiation in RCC: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors. Now on @JCOGO_ASCO our work by @aron_project
@IKCCorg @IntKidneyCancer @Uromigos @Unibo @MattRosellini @vmollica7 @MatteoSantoniMD
0
14
37
#ESMO25 | Where is the ARON Group heading next? Francesco Massari shares his tips. Catch the full feature and all other essential interviews with the ARON Group in the special post-ESMO OncoInfo edition!
0
1
1
@aron_project is more than an amazing collaborative research working group. It is a family. Thanks for this incredible journey. @MatteoSantoniMD @fmassari79 @drenriquegrande @JaviMolinaC @SoaresAndrey @vmollica7
0
3
12
The soul of Oncology, the spirit of science: the @aron_project. Thanks @myesmo for allowing us to meet at #ESMO25 Not easy to see a group with more scientific production in the field of GU. @OncoAlert @fsabino_onco @SoaresAndrey @fmassari79 @MatteoSantoniMD @raymanneh
5
16
63
#ESMO25 | Standing room only at the 2nd International ARON Meeting! Don't miss the special issue of OncoInfo from Berlin, entirely dedicated to the topic of RWE in #genitourinarytumors, coming out in a few days. Stay tuned! 📡 @drenriquegrande @SoaresAndrey @fmassari79
0
4
4
#RccConsensusConference 🎯 Just wrapped up the Italian Delphi Consensus Meeting on #RCC in Naples. Great discussions and valuable insights. - Belzutifan/Casdatifan - Personalization&Optimization - Ae and Fertility Preservation -QoL & FKFI-23 Results coming soon, stay tuned!!
1
6
26
0
9
16
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study Out now on EJC our last research by @aron_project
@oncodaily @OncoAlert
1
7
19
Another important masterpiece of @aron_project . @MatteoSantoniMD @SoaresAndrey @BourlonMaite @DrYukselUrun
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study Out now on EJC our last research by @aron_project
@oncodaily @OncoAlert
2
4
14
A prognostic score for mUC patients treated with immunotherapy. Just out at @MetastasisRS Journal. Congrats @MatteoSantoniMD @fmassari79 @SoaresAndrey @DrYukselUrun @aron_project
https://t.co/7czAzSJXbx
2
7
12
Out now on @EUplatinum our Words of Wisdom about nccRCC. “nccRCC reminds us that in the complexity of cancer lies an opportunity not just to cure, but also to understand.”
2
5
19
Out our first translational research from ARON-1α mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations. @MatteoSantoniMD @aron_project
1
5
14
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study https://t.co/NhHumMbtOG This multicenter, retrospective study evaluated the real-world efficacy of first-line immune-based combinations in 323
0
11
27
Latest Research on Immune-Based Combinations in Non–clear Cell Renal Cell Carcinoma - @fmassari79
@EurUrolFocus @aron_project
https://t.co/Oq9r2bxvDW
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX
0
2
16